ID   LAPC4-SL
AC   CVCL_WZ26
SY   Stem-Like LAPC4; LAPC4-Stem Like
DR   cancercelllines; CVCL_WZ26
DR   GEO; GSM1633308
DR   GEO; GSM1633309
DR   GEO; GSM1633310
DR   Wikidata; Q95981289
RX   PubMed=28145883;
CC   Characteristics: Reprogrammed to, maintained and propagated as cancer stem-like cells (CSCs) by growth in androgen-free neural/neural crest (N/NC) stem medium.
CC   Virology: Contains an integrated xenotropic MuLV-related virus (XMRV) Bxv-1 (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (from parent cell line).
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000027.
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_4744 ! LAPC-4
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 06-09-19; Last updated: 05-10-23; Version: 8
//
RX   PubMed=28145883; DOI=10.18632/oncotarget.14850;
RA   Nouri M., Caradec J., Lubik A.A., Li N., Hollier B.G., Takhar M.,
RA   Altimirano-Dimas M., Chen M.-Q., Roshan-Moniri M., Butler M., Lehman M.,
RA   Bishop J., Truong S., Huang S.-C., Cochrane D., Cox M., Collins C.,
RA   Gleave M.E., Erho N., Alshalafa M., Davicioni E., Nelson C.,
RA   Gregory-Evans S., Karnes R.J., Jenkins R.B., Klein E.A., Buttyan R.;
RT   "Therapy-induced developmental reprogramming of prostate cancer cells
RT   and acquired therapy resistance.";
RL   Oncotarget 8:18949-18967(2017).
//